FDA accepts Jardiance sNDA for T2D in children 10 and older
The US FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets as a potential treatment for children 10 years and older with type 2 diabetes
Cancer research is one of the cornerstones of BI's research and has resulted in the launch of 2 products for the treatment of non-small cell lung cancer.